# Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery

> **NCT02169284** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Bladder Carcinoma
- Recurrent Bladder Carcinoma

## Interventions

- **DRUG:** Erlotinib Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **OTHER:** Placebo
- **OTHER:** Quality-of-Life Assessment
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT02169284
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10-01
- **Primary completion:** 2018-03-30
- **Final completion:** 2018-03-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02169284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02169284, "Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02169284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*